Your browser is no longer supported. Please, upgrade your browser.
BPMC [NASD]
Blueprint Medicines Corporation
Index- P/E18.84 EPS (ttm)5.43 Insider Own0.60% Shs Outstand55.17M Perf Week-4.35%
Market Cap5.79B Forward P/E- EPS next Y-6.76 Insider Trans-36.46% Shs Float54.63M Perf Month-12.81%
Income333.20M PEG0.85 EPS next Q-1.62 Inst Own- Short Float5.03% Perf Quarter0.02%
Sales811.20M P/S7.14 EPS this Y-34.80% Inst Trans0.05% Short Ratio5.43 Perf Half Y30.50%
Book/sh23.93 P/B4.28 EPS next Y-223.40% ROA33.30% Target Price118.00 Perf Year26.20%
Cash/sh13.39 P/C7.64 EPS next 5Y22.27% ROE43.70% 52W Range43.29 - 125.61 Perf YTD-8.74%
Dividend- P/FCF16.06 EPS past 5Y-32.50% ROI-77.80% 52W High-17.62% Beta0.69
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin100.00% 52W Low139.04% ATR4.68
Employees420 Current Ratio7.60 Sales Q/Q8053.20% Oper. Margin40.10% RSI (14)41.41 Volatility3.80% 4.60%
OptionableYes Debt/Eq0.00 EPS Q/Q679.30% Profit Margin41.10% Rel Volume0.31 Prev Close102.35
ShortableYes LT Debt/Eq0.00 EarningsOct 29 BMO Payout0.00% Avg Volume506.24K Price103.48
Recom1.90 SMA20-7.34% SMA50-3.88% SMA20021.98% Volume123,107 Change1.10%
Dec-03-20Initiated Stifel Hold $110
Nov-02-20Reiterated H.C. Wainwright Buy $110 → $135
Nov-02-20Downgrade Jefferies Buy → Hold $90 → $96
Oct-30-20Downgrade Morgan Stanley Overweight → Equal-Weight $112
Jul-15-20Reiterated H.C. Wainwright Buy $66 → $110
May-05-20Initiated Barclays Equal Weight $59
Mar-17-20Upgrade BMO Capital Markets Market Perform → Outperform $74 → $89
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Nov-06-19Upgrade Raymond James Outperform → Strong Buy $106 → $112
Oct-22-19Initiated JMP Securities Mkt Outperform $106
Oct-03-19Initiated H.C. Wainwright Buy $100
Sep-12-19Upgrade Raymond James Mkt Perform → Outperform
Aug-29-19Initiated Piper Jaffray Neutral $85
Aug-15-19Resumed Raymond James Mkt Perform
Jul-18-19Initiated Deutsche Bank Buy $110
May-23-19Resumed Goldman Buy $125
Apr-03-19Initiated Morgan Stanley Overweight $112
Sep-25-18Initiated Leerink Partners Outperform
Dec-11-17Reiterated Goldman Buy $82 → $99
Jan-20-21 12:00PM  
Jan-13-21 09:42AM  
Jan-11-21 11:22AM  
08:05AM  
08:00AM  
Jan-08-21 09:05AM  
Jan-05-21 04:01PM  
Jan-04-21 09:30AM  
Dec-31-20 08:46AM  
Dec-30-20 11:33PM  
Dec-22-20 05:08PM  
Dec-21-20 01:59PM  
Dec-17-20 08:00AM  
Dec-07-20 08:00AM  
Dec-04-20 04:01PM  
Dec-02-20 10:50AM  
Dec-01-20 03:15PM  
Nov-23-20 08:00AM  
Nov-03-20 04:05PM  
04:01PM  
Nov-01-20 07:43AM  
Oct-30-20 08:09AM  
Oct-29-20 11:17AM  
08:35AM  
07:38AM  
07:00AM  
06:30AM  
Oct-26-20 11:54PM  
Oct-22-20 08:00AM  
Oct-02-20 04:01PM  
Sep-30-20 07:17AM  
Sep-29-20 11:46AM  
Sep-28-20 12:38PM  
Sep-25-20 11:46AM  
Sep-23-20 12:54PM  
09:30AM  
08:05AM  
Sep-22-20 04:23PM  
07:00AM  
Sep-20-20 08:25AM  
Sep-17-20 08:00AM  
Sep-13-20 07:27AM  
Sep-09-20 08:29PM  
04:01PM  
Sep-04-20 07:00PM  
08:00AM  
Sep-01-20 08:00AM  
Aug-29-20 11:31AM  
Aug-04-20 08:00AM  
Aug-01-20 08:21AM  
Jul-31-20 11:18AM  
Jul-30-20 08:35AM  
07:28AM  
07:00AM  
Jul-24-20 08:30AM  
Jul-23-20 08:00AM  
Jul-14-20 05:22PM  
12:23PM  
12:22PM  
08:28AM  
08:04AM  
06:23AM  
03:56AM  
01:00AM  
Jul-13-20 08:25PM  
Jul-02-20 04:01PM  
12:25PM  
Jul-01-20 08:00AM  
Jun-29-20 06:30PM  
Jun-06-20 09:00AM  
Jun-05-20 11:32AM  
Jun-03-20 08:00AM  
07:11AM  
03:05AM  
May-29-20 01:13PM  
08:00AM  
May-27-20 04:30PM  
May-26-20 08:00AM  
May-18-20 12:16PM  
May-15-20 12:10PM  
08:00AM  
May-14-20 11:29PM  
12:00PM  
09:00AM  
May-12-20 11:36AM  
May-07-20 12:58PM  
08:01AM  
May-06-20 08:35AM  
07:00AM  
Apr-28-20 11:19AM  
10:27AM  
07:00AM  
Apr-16-20 06:30AM  
Apr-09-20 12:00PM  
Apr-01-20 08:00AM  
Mar-27-20 03:51PM  
Mar-16-20 07:00AM  
Mar-14-20 11:30AM  
Mar-09-20 09:00AM  
Mar-06-20 06:10AM  
Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Demetri GeorgeDirectorJan 04Sale112.1575885,0103,562Jan 06 04:14 PM
Goldberg Mark AlanDirectorDec 24Option Exercise28.155,455153,5589,017Dec 28 04:23 PM
Goldberg Mark AlanDirectorDec 24Sale125.005,455681,8753,562Dec 28 04:23 PM
Goldberg Mark AlanDirectorDec 18Option Exercise28.155,454153,5309,016Dec 22 04:14 PM
Goldberg Mark AlanDirectorDec 18Sale120.005,454654,4803,562Dec 22 04:14 PM
Rowland Charles A JrDirectorDec 17Option Exercise19.5310,909213,05314,471Dec 18 04:09 PM
Rowland Charles A JrDirectorDec 17Sale117.8210,9091,285,2983,562Dec 18 04:09 PM
Albers Jeffrey W.CEO and PresidentDec 14Option Exercise8.805,00044,000146,434Dec 16 04:04 PM
Dorsch MarionChief Scientific OfficerDec 14Option Exercise37.114,600170,70619,850Dec 16 04:03 PM
Boral Anthony L.Chief Medical OfficerDec 14Option Exercise15.0110,000150,10038,147Dec 16 04:03 PM
Boral Anthony L.Chief Medical OfficerDec 14Sale118.5210,0001,185,20028,147Dec 16 04:03 PM
Dorsch MarionChief Scientific OfficerDec 14Sale119.004,600547,40015,250Dec 16 04:03 PM
Albers Jeffrey W.CEO and PresidentDec 14Sale119.185,000595,900141,434Dec 16 04:04 PM
Goldberg Mark AlanDirectorDec 11Option Exercise28.155,455153,5589,017Dec 15 04:08 PM
Goldberg Mark AlanDirectorDec 11Sale115.005,455627,3253,562Dec 15 04:08 PM
Hurley ArielPrincipal Accounting OfficerDec 01Option Exercise8.809007,92010,884Dec 03 04:10 PM
Goldberg Mark AlanDirectorDec 01Option Exercise28.155,454153,5309,016Dec 03 04:10 PM
Goldberg Mark AlanDirectorDec 01Sale110.005,454599,9403,562Dec 03 04:10 PM
Hurley ArielPrincipal Accounting OfficerDec 01Sale109.881,038114,0539,984Dec 03 04:10 PM
Hurley ArielPrincipal Accounting OfficerNov 16Option Exercise3.091,7005,25811,684Nov 18 04:21 PM
Albers Jeffrey W.CEO and PresidentNov 16Option Exercise8.8020,000176,000161,434Nov 18 04:22 PM
Haviland KateChief Operating OfficerNov 16Option Exercise36.0540914,74443,247Nov 18 04:23 PM
Haviland KateChief Operating OfficerNov 16Sale100.2740941,01042,838Nov 18 04:23 PM
Albers Jeffrey W.CEO and PresidentNov 16Sale98.7120,0001,974,295141,434Nov 18 04:22 PM
Hurley ArielPrincipal Accounting OfficerNov 16Sale100.921,700171,5649,984Nov 18 04:21 PM
Rowland Charles A JrDirectorNov 03Option Exercise9.465,52252,2389,084Nov 04 05:18 PM
Rowland Charles A JrDirectorNov 03Sale98.735,522545,1963,562Nov 04 05:18 PM
Rossi ChristinaChief Commercial OfficerNov 03Sale99.6934534,39320,020Nov 05 05:02 PM
Rowland Charles A JrDirectorNov 02Option Exercise9.464,47842,3628,040Nov 04 05:18 PM
Rowland Charles A JrDirectorNov 02Sale99.114,478443,8153,562Nov 04 05:18 PM
Boral Anthony L.Chief Medical OfficerOct 23Option Exercise12.709,183116,66728,147Oct 27 04:05 PM
Goldberg Mark AlanDirectorOct 19Option Exercise19.535,455106,5369,017Oct 21 04:21 PM
Goldberg Mark AlanDirectorOct 19Sale105.005,455572,7753,562Oct 21 04:21 PM
Haviland KateChief Operating OfficerOct 16Option Exercise36.0513,334480,69156,172Oct 20 04:09 PM
Haviland KateChief Operating OfficerOct 16Sale101.2313,3341,349,84842,838Oct 20 04:09 PM
Goldberg Mark AlanDirectorOct 07Option Exercise19.535,454106,5179,016Oct 09 04:04 PM
Albers Jeffrey W.CEO and PresidentOct 07Option Exercise8.805,00044,000146,434Oct 09 04:05 PM
Hurley ArielPrincipal Accounting OfficerOct 07Option Exercise8.806005,28010,584Oct 09 04:06 PM
Hurley ArielPrincipal Accounting OfficerOct 07Sale100.0060060,0009,984Oct 09 04:06 PM
Albers Jeffrey W.CEO and PresidentOct 07Sale99.175,000495,850141,434Oct 09 04:05 PM
Goldberg Mark AlanDirectorOct 07Sale100.005,454545,4003,562Oct 09 04:04 PM
Dorsch MarionChief Scientific OfficerOct 06Option Exercise37.114,600170,70619,850Oct 08 04:16 PM
Dorsch MarionChief Scientific OfficerOct 06Sale99.004,600455,40015,250Oct 08 04:16 PM
Lydon NicholasDirectorOct 01Sale93.089,815913,59537,425Oct 05 04:17 PM
Durso-Bumpus DebraChief People OfficerSep 23Option Exercise36.051,90068,49521,405Sep 25 04:26 PM
Dorsch MarionChief Scientific OfficerSep 23Option Exercise37.114,600170,70619,850Sep 25 04:27 PM
Hurley ArielPrincipal Accounting OfficerSep 23Option Exercise1.871,4002,61811,384Sep 25 04:27 PM
Hurley ArielPrincipal Accounting OfficerSep 23Sale90.001,400126,0009,984Sep 25 04:27 PM
Dorsch MarionChief Scientific OfficerSep 23Sale89.004,600409,40015,250Sep 25 04:27 PM
Durso-Bumpus DebraChief People OfficerSep 23Sale90.021,900171,03819,505Sep 25 04:26 PM
Haviland KateChief Operating OfficerSep 22Option Exercise16.283,14351,16845,981Sep 24 04:19 PM
Boral Anthony L.Chief Medical OfficerSep 22Option Exercise15.016,864103,02925,828Sep 24 04:22 PM
Demetri GeorgeDirectorSep 22Sale85.001,704144,8404,320Sep 24 04:22 PM
Boral Anthony L.Chief Medical OfficerSep 22Sale82.336,864565,11318,964Sep 24 04:22 PM
Haviland KateChief Operating OfficerSep 22Sale85.493,143268,69542,838Sep 24 04:19 PM
Boral Anthony L.Chief Medical OfficerSep 17Option Exercise11.4523,136264,94542,100Sep 21 04:22 PM
Boral Anthony L.Chief Medical OfficerSep 17Sale80.0023,1361,850,88018,964Sep 21 04:22 PM
Lydon NicholasDirectorSep 17Sale80.0050040,00047,240Sep 21 04:21 PM
Albers Jeffrey W.CEO and PresidentAug 19Option Exercise8.8020,000176,000161,434Aug 21 04:22 PM
Albers Jeffrey W.CEO and PresidentAug 19Sale75.0220,0001,500,438141,434Aug 21 04:22 PM
Hurley ArielPrincipal Accounting OfficerAug 17Option Exercise1.877001,30910,684Aug 19 04:52 PM
Hurley ArielPrincipal Accounting OfficerAug 17Sale75.0070052,5009,984Aug 19 04:52 PM
Lydon NicholasDirectorJul 06Sale80.4526,0072,092,35147,740Jul 08 04:25 PM
Lydon NicholasDirectorJul 02Sale80.132,825226,36773,747Jul 06 06:30 PM
Lydon NicholasDirectorJul 01Sale80.211,300104,27376,572Jul 06 06:30 PM
Lydon NicholasDirectorJun 23Sale80.0040032,00075,622Jun 25 04:10 PM
Durso-Bumpus DebraChief People OfficerJun 22Option Exercise36.052,30082,91521,805Jun 24 04:14 PM
Durso-Bumpus DebraChief People OfficerJun 22Sale80.072,300184,16119,505Jun 24 04:14 PM
Lydon NicholasDirectorJun 22Sale80.2913,0171,045,13576,022Jun 23 04:13 PM
Dorsch MarionChief Scientific OfficerJun 19Option Exercise37.114,600170,70619,850Jun 23 04:10 PM
Dorsch MarionChief Scientific OfficerJun 19Sale79.004,600363,40015,250Jun 23 04:10 PM
Durso-Bumpus DebraChief People OfficerJun 18Option Exercise18.002,50045,00022,005Jun 22 04:21 PM
Durso-Bumpus DebraChief People OfficerJun 18Sale75.182,500187,95019,505Jun 22 04:21 PM
Hurley ArielPrincipal Accounting OfficerJun 09Option Exercise1.877001,30910,684Jun 11 05:20 PM
Hurley ArielPrincipal Accounting OfficerJun 09Sale75.0070052,5009,984Jun 11 05:20 PM
Hurley ArielPrincipal Accounting OfficerJun 02Sale66.0323515,5179,984Jun 04 04:37 PM
Albers Jeffrey W.CEO and PresidentMay 12Option Exercise8.8020,000176,000161,434May 14 04:38 PM
Albers Jeffrey W.CEO and PresidentMay 12Sale64.6720,0001,293,427141,434May 14 04:38 PM
Albers Jeffrey W.CEO and PresidentMar 23Option Exercise5.3240,000212,846161,434Mar 25 04:22 PM
Albers Jeffrey W.CEO and PresidentMar 23Sale52.1020,0001,041,922141,434Mar 25 04:22 PM
Dorsch MarionChief Scientific OfficerMar 23Sale52.491,21463,72615,250Mar 25 04:22 PM
Hurley ArielPrincipal Accounting OfficerMar 09Sale51.9425313,1419,984Mar 11 04:32 PM
Boral Anthony L.Chief Medical OfficerMar 09Sale51.9753627,85618,964Mar 11 04:31 PM
Albers Jeffrey W.CEO and PresidentMar 09Sale51.972,277118,336121,434Mar 11 04:31 PM
Durso-Bumpus DebraChief People OfficerMar 09Sale51.9443222,43819,505Mar 11 04:30 PM
Dorsch MarionChief Scientific OfficerMar 09Sale51.9953627,86716,464Mar 11 04:30 PM
Landsittel MichaelChief Financial OfficerMar 09Sale51.9740020,78817,350Mar 11 04:29 PM
Haviland KateChief Operating OfficerMar 09Sale51.9867134,87942,838Mar 11 04:29 PM
Rossi ChristinaChief Commercial OfficerMar 09Sale51.961357,01520,365Mar 11 04:27 PM
Murray Christopher K.SVP, Technical OperationsMar 09Sale51.9440220,88013,848Mar 11 04:28 PM
McCain Tracey LEVP and Chief Legal OfficerMar 09Sale51.9861732,07221,683Mar 11 04:28 PM
Haviland KateChief Operating OfficerMar 03Option Exercise16.284,64475,60443,509Mar 03 07:12 PM